Genentech sues Biogen for debt over blockbuster MS drug

Published Date: 08 Mar 2023

Roche's Genentech Inc sued Biogen MA Inc in federal court in San Francisco, alleging that Biogen owed additional patent royalties from worldwide sales of its blockbuster multiple sclerosis and Crohn's disease drug, Tysabri.

Read Full News

Latest News

EHR Marker May Help Curb Risk for Liver Transplant Rejection

A remote intervention aimed at improving medication adherence may reduce organ rejection in liver transplant recipients at high risk.

Altimmune Drug Cuts Heavy Drinking in Mid-stage Trial for Alcohol Use Disorder

Altimmune said on Tuesday its experimental drug helped patients with alcohol use disorder cut back on heavy drinking ⁠in a mid-stage trial, sending the company's shares 10%...

Newer Antibiotics Show No Clear Benefit for Staph Infections

A new meta-analysis finds ceftaroline and ceftobiprole monotherapy show no clear advantage over standard therapy for non-urinary Staphylococcus aureus infections.

FDA Approves Freenome's Blood Test for Colorectal Cancer Screening

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way ⁠for partner Abbott to launch it in the U.S. this fall,...

Company At Center Of US Cyclospora Outbreak Complained to White House, Source Says

U.S. produce supplier Taylor Farms complained to White House and Food and Drug Administration officials about the government's inspection process earlier this month, a...

Poultry Firm Recalls Nearly 1.6 Million Dozen Eggs Over Salmonella Risk, FDA Says

The U.S. FDA said on Wednesday that Midwest Poultry Services is recalling nearly 1.6 ⁠million dozen eggs produced in Texas due to potential Salmonella...

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Todays Updates

Trial Challenges Indefinite Maintenance for Multiple Myeloma

A randomized trial questions whether patients with standard-risk multiple myeloma need indefinite lenalidomide maintenance.

Blinatumomab May Improve Survival in High-Risk Adult B-ALL

A phase 2 trial evaluates the benefit of adding blinatumomab to consolidation therapy in adults with high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Latest News

A remote intervention aimed at improving medication adherence may reduce organ rejection in liver transplant recipients at high risk.

Altimmune said on Tuesday its experimental drug helped patients with alcohol use disorder cut back on heavy drinking ⁠in a mid-stage trial, sending the company's shares 10%...

A new meta-analysis finds ceftaroline and ceftobiprole monotherapy show no clear advantage over standard therapy for non-urinary Staphylococcus aureus infections.

The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way ⁠for partner Abbott to launch it in the U.S. this fall,...

U.S. produce supplier Taylor Farms complained to White House and Food and Drug Administration officials about the government's inspection process earlier this month, a...

The U.S. FDA said on Wednesday that Midwest Poultry Services is recalling nearly 1.6 ⁠million dozen eggs produced in Texas due to potential Salmonella...

News All Time

Beware Aspiration Risk in Chronic Pot Users

A cautionary tale of gastroparesis-related aspiration in NPO patient with no other risk factors

Unusual Confluence of Two Rare Syndromes Results in Peculiar Symptoms

Interpretation of an ultrasound exam made all the difference in creating a treatment plan

Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

— Results highlight importance of careful evaluation of concurrent medications, researchers say

Q&A: Managing GI Toxicities of Immunotherapy

Gastrointestinal side effects are among the most important issues to address with patients starting on immune checkpoint inhibitors.

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Equitable IBD Care: Improving Interactions With Patients From the LGBTQ+ Community

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Mastering Recent Advances in Targeted Therapy for GEP-NETs

Steatosis and Cardiovascular Events; Golimumab Biosimilar OK'd; Daily Stress and IBS

News and commentary from the world of gastroenterology and hepatology

GLP-1s Linked to Lower Risk of Cancer Spread in Four Tumor Types

Accumulating evidence of possible benefit warrants randomized trials, experts say

Danish Duo's Maverick African Research Finds Its Moment in RFK Jr.'s Vaccine Policy

"They became more strident in saying that their findings were real," says one expert

FDA OKs First Treatment for Chronic Hepatitis D Infection

In phase III study, patients taking bulevirtide had ALT normalization and steep drops in HDV RNA

Blood Test for Colon Cancer Screening Gets Guideline Backing

Updated ACS guidance suggests use in those who decline other options

Perfusion Preservation Strategy Boosts Liver Transplant Outcomes

Portal-venous hypothermic oxygenated perfusion reduced incidence of early allograft dysfunction

Novel Hep B Drug Delivers Functional Cures in Late-Stage Trials

Findings "will change the landscape" of treatment, researcher says

GLP-1s and Chronic Pancreatitis; Hypoglycemia After Bowel Prep; Lower GI Bleeding

News and commentary from the world of gastroenterology and hepatology

TIPS Was Tops for Refractory Hydrothorax in Cirrhosis

Majority of patients who received TIPS had a complete clinical response

Enhanced MRI Tops Ultrasound in Catching Early Liver Cancer

MRI approach also led to fewer false referrals

Recommended News For You

Microplastics can cause malignant changes in lung cells

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

BMI is linked to heart damage from chemotherapy in breast cancer patients.

Momelotinib, a JAK inhibitor, has FDA approval to treat adult myelofibrosis in anemic patients.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

Cancer Diagnoses Still Lagging; Cancer and Family Health; New Type of Lung Cancer

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Recommended Articles For You

Innovative Marketing Strategies for Oncology Drugs: A Clinician’s Take on Digital and B2B Trends 

Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights 

Uncovering the Mystery of the Sessile Serrated Adenoma 

Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".

2.

Black women have a higher risk of dying from all types of breast cancer, meta-analysis reveals

3.

Second opinions don't significantly delay breast cancer treatment

4.

Year in Review: Multiple Myeloma

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

1.

The importance of understanding normal serum osmolality

2.

Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post

3.

What is Red Cell Distribution Width and Why Should You Care?

4.

Metabolic Vulnerabilities in Solid Tumor Progression

5.

Exploring the Normal Range of Monocytes: A Comprehensive Guide

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

3.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII

5.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot